Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life
European Journal of Neurology · 2024-12 · 31 (12)
DOI: 10.1111/ene.16437 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 12.08.2024. Verfasst von Uwe Reuter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charite Universitatsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Topiramate, Migraine Disorders, Antibodies, Monoclonal, Humanized, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma.
Abstract (Originalsprache)
Background and purpose HER‐MES was the first head‐to‐head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER‐MES study evaluated the effect of erenumab versus topiramate on patient‐reported outcomes at week 24.
Methods
Adult patients with episodic or chronic migraine ( n = 777) were randomized (1:1) to monthly subcutaneous erenumab ( n = 389) or daily oral topiramate ( n = 388). Migraine‐related disability, as measured by the Headache Impact Test 6 (HIT‐6) and Short Form 36 Health Survey version 2 (SF‐36v2), was analysed in the entire study cohort and true completers.
Results
In the erenumab group (vs. topiramate), significant improvements were reported in Headache Impact Test 6 total scores (composite populations, −10.88 vs. −7.72; true completers, −11.92 vs. −10.61) and a higher proportion of patients achieved a ≥5‐point reduction from baseline with erenumab (composite populations, 72.2% vs. 53.9%; true completers, 79.64% vs. 71.43%). The adjusted mean change from baseline in the SF‐36v2 score was greater with erenumab for both physical component summary (composite population, 5.48 vs. 3.63; true completers, 5.95 vs. 5.23) and mental component summary (composite populations, 1.00 vs. −1.18; true completers, 1.74 vs. −0.33). A higher proportion of patients on erenumab versus topiramate had a ≥5‐point improvement in SF‐36v2 for the physical component summary (composite populations, 47.7% vs. 37.4%; true completers, 52.1% vs. 48.9%) and mental component summary (composite populations, 25.3% vs. 16.8%; true completers, 27.3% vs. 17.7%).
Conclusions
This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient‐reported outcomes versus patients treated with topiramate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Charite Universitatsmedizin Berlin, Berlin, Germany.
- Universitatsmedizin Greifswald, Greifswald, Germany.
- Schmerzklinik Kiel, Migraine and Headache Center, Kiel, Germany.
- Praxis Gendolla, Essen, Germany.
- Novartis Pharma GmbH, Nuremberg, Germany.
ORCID-Profile: Uwe Reuter
Förderung
- Novartis Pharma
Zitieren
APA
Reuter, U., Heinze, A., Gendolla, A., Sieder, C., & Hentschke, C. (2024). Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16437
Vancouver
Reuter U, Heinze A, Gendolla A, Sieder C, Hentschke C. Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16437
BibTeX
@article{Reuter2024,
author = {Reuter, Uwe and Heinze, Axel and Gendolla, Astrid and Sieder, Christian and Hentschke, Christian},
title = {Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {12},
doi = {10.1111/ene.16437}
}
EUVIMED